Fig. 6

Overall survival among cancer patients with high and low TMB. a Kaplan-Meier curves for immunotherapy-treated (+ICI) and immunotherapy-naive (−ICI) Stage III-IV melanoma patients with high TMB (> 80th percentile) are shown in red, and dark gray, respectively, while immunotherapy-treated (+ICI) and immunotherapy-naive (−ICI) patients with low TMB (≤ 80th percentile) are shown in blue and light gray, respectively. The underlying table corresponds to the number of patients at risk of death at each timepoint. Note: TCGA SKCM patient data (−ICI) is censored at 2885 days (maximal follow-up in immunotherapy-treated cohort) to emphasize comparable time-scales. b Kaplan-Meier curves for the immunotherapy-treated (+ICI) and immunotherapy-naive (−ICI) metastatic (Stage IV) renal cell carcinoma patients with high TMB (> 80th percentile) are shown in red, and dark gray, respectively, while immunotherapy-treated (+ICI) and immunotherapy-naive (−ICI) patients with low TMB (≤ 80th percentile) are shown in blue and light gray, respectively. The underlying table corresponds to the number of patients at risk of death at each timepoint. Note: TCGA KIRC patient data is censored at 1724 days (maximal follow-up in immunotherapy-treated cohort) to emphasize comparable time-scales